First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland-Reference-Cited by-同舟云学术

First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland

Published:2021-03 Issue:4 Volume:13 Page:297-307
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Cybulska-Stopa Bożena¹^ORCID,Pacholczak-Madej Renata¹²^ORCID,Kamińska-Winciorek Grażyna³^ORCID,Ziętek Marcin⁴⁵^ORCID,Czarnecka Anna M⁶⁷^ORCID,Piejko Karolina¹^ORCID,Galus Łukasz⁸⁹^ORCID,Ziółkowska Barbara¹⁰^ORCID,Kieszko Stanisław¹¹,Kempa-Kamińska Natasza¹²^ORCID,Calik Jacek¹²^ORCID,Rolski Janusz¹,Sałek-Zań Agata¹^ORCID,Gajewska-Wicher Katarzyna¹^ORCID,Drosik-Kwaśniewska Anna¹,Rogala Paweł⁶^ORCID,Kubiatowski Tomasz¹¹^ORCID,Suwiński Rafał¹⁰^ORCID,Mackiewicz Jacek⁸¹³^ORCID,Rutkowski Piotr⁶^ORCID

Affiliation:

1. Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, 31-115 Krakow, Poland

2. Department of Anatomy, Jagiellonian University, Medical College, 31-543 Krakow, Poland

3. Department of Bone Marrow Transplantation & Hematology-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland

4. Department of Oncological Surgery – Skin Cancer Unit, Lower Silesian Oncology Center, 53-413 Wroclaw, Poland

5. Department of Oncological Surgery, Wroclaw Medical University, 53-413 Wroclaw, Poland

6. Department of Soft Tissue/Bone Sarcoma & Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland

7. Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland

8. Department of Medical & Experimental Oncology, Poznan University of Medical Sciences, 60-786 Poznan, Poland

9. Chemotherapy Department, Greater Poland Cancer Centre, 61-866 Poznan, Poland

10. II Clinic of Radiotherapy & Chemotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, 44-102 Gliwice, Poland

11. Department of Clinical Oncology, Saint Jan of Dukla Oncology Centre of the Lublin Region, 20-090 Lublin, Poland

12. Department of Clinical Oncology, Lower Silesian Oncology Center, 53-413 Wroclaw, Poland

13. Department of Diagnostics & Cancer Immunology, Greater Poland Cancer Centre, 61-866 Poznan, Poland

Abstract

Aim: To evaluate treatment results in advanced/metastatic melanoma patients treated with anti-PD-1 immunotherapy in routine practice in oncology centers in Poland. Methods: Multicenter retrospective analysis included 499 patients with unresectable/metastatic (stage IIIC–IV) melanoma treated with anti-PD-1 in first-line therapy. Results: Estimated median overall survival (OS) and progression-free survival (PFS) were 19.9 and 7.9 months, respectively. Multivariate analysis confirmed that ECOG 0, no brain metastases, normal lactate dehydrogenase level and occurrence of immune-related adverse events (irAEs) were statistically significantly associated with improved OS and PFS. Any irAE occurred in 24% of patients. Grade 3 or Grade 4 irAEs occurred in 6% of patients. Conclusion: Analysis revealed a slightly worse OS in real-world treatment in comparison to clinical trials (KEYNOTE-006 and CheckMate 066). Polish population treatment results are similar to other studies of real-world data. PFS and ORR are similar in our research and clinical trials.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2020-0217

Reference40 articles.

1. Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

2. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

3. Pembrolizumab versus Ipilimumab in Advanced Melanoma

4. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors;Cancers;2024-01-05

2. Vitamin D supplementation increases objective response rate and prolongs progression‐free time in patients with advanced melanoma undergoing anti–PD‐1 therapy;Cancer;2023-04-24

3. Common statement of experts of the Polish Oncological Society, Polish Lung Cancer Group, Polish Society of Lung Diseases, Polish Society of Gastroenterology, Polish Society of Endocrinology, and the Polish Society of Cardiology for minimal requirements in diagnosis and monitoring of selected adverse events of immunotherapy in oncological patients;Oncology in Clinical Practice;2023-04-21

4. Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience;Biomedicines;2022-10-10

5. New Zealand national retrospective cohort study of survival outcomes of patients with metastatic melanoma receiving immune‐checkpoint inhibitors;Asia-Pacific Journal of Clinical Oncology;2022-06-10